Letters |

Stem Cell Therapy in Kidney Transplantation

Leonardo V. Riella, MD, PhD; Anil Chandraker, MD
JAMA. 2012;308(2):130-131. doi:10.1001/jama.2012.6370.
Text Size: A A A
Published online


To the Editor: Dr Tan and colleagues reported a randomized controlled trial using autologous mesenchymal stem cells (MSCs) as induction therapy in living-related kidney transplants.1 We would like clarification of some technical aspects regarding the preparation of the MSCs, safety measures, and infusion site because of some concerns about potential unexpected complications of MSC therapy in a phase 1 clinical trial with MSCs in kidney transplantation.2 Specifically, the authors should describe what type of serum was used in cultures, the method applied for detachment of MSCs from the culture plate, and if MSC markers were checked prior to every infusion. Based on recent animal data reporting the appearance of visceral tumors following MSC therapy,3 it would also be important to document cancer complications in the first year after kidney transplantation. In addition, the site of infusion of MSCs (peripheral vein vs renal artery) might have an important role in the outcome because some studies suggest that most MSCs get lodged in pulmonary capillaries when injected into peripheral veins.4


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




July 11, 2012
Jianming Tan, MD, PhD; Antonello Pileggi, MD, PhD; Camillo Ricordi, MD
JAMA. 2012;308(2):130-131. doi:10.1001/jama.2012.6372.
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...